Read more

August 15, 2022
1 min read
Save

Top in cardiology: PCSK9 inhibition; new AHA president’s goals

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

A recent study found that PCSK9 inhibition did not affect cognitive function or dementia risk.

However, there may be an association between statin use and some impaired cognitive performance, according to researchers. It was the top story in cardiology last week.

3D Anatomical Heart_297050149
Source: Adobe Stock

Another top story was an exclusive interview with the American Heart Association’s new president, Michelle A. Albert, MD, MPH, FACC, FAHA, the first black woman to serve in the position.

Read these and more top stories in cardiology below:

No dementia, cognitive risk with PCSK9 inhibition; statin findings mixed

Data from a genetics-based study show PCSK9 inhibition does not affect cognition function or dementia risk; however, statin use may be associated with some impaired cognitive performance that is outweighed by any cardiovascular benefits. Read more.

‘Focus on the workforce’: New AHA president outlines goals for improving research, CV care

Healio spoke with Albert about her goals for the AHA moving forward, including improving workforce development throughout the pipeline, addressing economic adversity as a cardiovascular health issue and removing barriers to health care. Read more.

AF a risk factor for dementia in adults younger than 70 years

Atrial fibrillation conferred elevated risk for dementia in adults younger than 70 years, according to study findings published in the Journal of the American Heart Association.

Read more.

Meta-analysis: Rhythm control with catheter ablation ‘preferred treatment’ in AF, HFrEF

In patients with atrial fibrillation and concurrent heart failure with reduced ejection fraction, catheter ablation significantly reduced all-cause mortality compared with medical therapy, according to a new meta-analysis. Read more.

Noninvasive biomarker platform for fluid assessment in HF cleared

Bodyport announced its noninvasive biomarker platform, made in the form of a scale, received FDA clearance for measurement of fluid status and heart function in patients requiring fluid management. Read more.